Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) EPS (Weighted Average and Diluted) (2021 - 2025)

Senti Biosciences has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at -$0.48 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 22.58% year-over-year to -$0.48; the TTM value through Dec 2025 reached -$3.14, up 73.9%, while the annual FY2025 figure was -$2.73, 77.31% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.48 at Senti Biosciences, up from -$0.69 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.09 in Q4 2022 and troughed at -$6.98 in Q4 2023.
  • A 5-year average of -$2.46 and a median of -$2.45 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 102.45% in 2022 and later crashed 7855.56% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$3.67 in 2021, then soared by 102.45% to $0.09 in 2022, then crashed by 7855.56% to -$6.98 in 2023, then soared by 91.12% to -$0.62 in 2024, then rose by 22.58% to -$0.48 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for SNTI at -$0.48 in Q4 2025, -$0.69 in Q3 2025, and -$0.56 in Q2 2025.